IXICO plc announced a collaboration agreement with IMEKA Solutions Inc. to provide access to Imeka's suite of services for white matter1 imaging deployed in Alzheimer's Disease (AD) and Multiple Sclerosis (MS) clinical trials, amongst other CNS indications. Imeka's diffusion MRI algorithms will be made available to IXICO's global biopharma clients, streamlining access to these tools through a combined study delivery. With a single contracting line, this simplifies the procurement process whilst improving access to a broader suite of white matter imaging AI tools and solutions delivered by IXICO.

White matter imaging is of increasing interest for neuroinflammation, axonal integrity and myelin integrity, in particular in AD and MS clinical trials amongst other CNS indications.